Skip to content


Image of Joseph Patti PhD

Dr. Patti joined the Company in November 2012 and served as its Executive Vice President of Corporate Development and Strategy until October 1, 2014, when he was appointed as the Company’s President and Chief Executive Officer and a director. Prior to joining the Company, Dr. Patti co-founded Inhibitex, Inc. in 1998 and served as its Chief Scientific Officer and Senior Vice President of Research and Development from 2007 until it was acquired by Bristol Myers Squibb in February 2012. He also served as its Chief Scientific Officer and Vice President of Research and Development from 2005 to 2007 and as Vice President, Preclinical Development prior to that. Before co-founding Inhibitex, Dr. Patti was an Assistant Professor at Texas A&M's Institute of Biosciences and Technology and also served on the faculty at the University of Texas Health Science Center Graduate School of Biomedical Sciences. Dr. Patti received a B.S. in Microbiology from the University of Pittsburgh, an M.S.P.H. from the University of Miami, School of Medicine and a Ph.D. in Biochemistry from the University of Alabama at Birmingham. Dr. Patti was a director of SciStem Therapeutics, Inc. from 2012 to 2015. Dr. Patti was a director of Inhibitex from 1998 to 2005. 

Image of Mark Colonnese

Mr. Colonnese was appointed the Chief Financial Officer and Executive Vice President in November 2015.

Previously, Mr. Colonnese served as the Chief Financial Officer of Stealth BioTherapeutics since November 2014 and as the Executive Vice President and Chief Financial Officer of Transgenomic Inc. from  August 2012 to October 2014. Prior to that, he worked at Salutria Pharmaceuticals, LLC and at its predecessor company, AtheroGenics Inc., from 1999 to 2012, where he served in a number of executive roles, most recently as Executive Vice President, Commercial Operations and Chief Financial Officer . He has also held executive positions at Applied Analytical Industries and Schering-Plough, and served on the Board of Directors of Endeavor Pharmaceuticals, Inc.

Mr. Colonnese holds an M.B.A. Degree from Fairleigh Dickinson University and a B.S. magna cum laude from Ithaca College. He is a Certified Public Accountant (inactive).

Image of John Vernachio PhD

Dr John Vernachio joined Biota in 2014.

Dr. Vernachio served as Vice President for Research with the Arthritis Foundation in 2013. Prior to that, he served as Vice President of Biology for Inhibitex, Inc. from 1998 until 2012. From 1997 – 1998 Dr. Vernachio was Director of Life Sciences for Valentis, Inc. and from 1991 – 1997 served as Manager, Molecular Immunology for the Gene Therapy Unit of Baxter Healthcare.

Dr. Vernachio attended the University of Vermont where he earned a BS in Animal Science in 1984 and Johns Hopkins University School of Medicine where he completed a Ph.D. in biochemistry with a concentration in immunology and molecular biology in 1989. He completed his post-doctoral training in the Department of Immunology at The Research Institute of Scripps Clinic in San Diego in 1991.

Image of Anna Novotney-Barry

Anna Novotney-Barry joined Biota as Vice President of Clinical Development in November 2013.

Mrs. Novotney-Barry served as Vice President Clinical Development at Inhibitex, Inc. from March 2010 until August 2012, where compounds in clinical development included both small molecule anti-virals to treat Hepatitis C and Herpes Zoster as well as a monoclonal antibody directed at  bacterial infection.  Prior to Inhibitex, she held several global scientific and management positions within Clinical Development at UCB Pharma SA, including responsibility for leading clinical program development for certain monoclonal antibodies within the immunology therapeutic area.  Earlier in her career which spans more than 25 years, she held a number of positions within Clinical Development or Drug Discovery at Solvay, Cryolife, and Searle.

Mrs. Novotney-Barry received a B.S. degree in Biology from the University of Illinois at Champaign-Urbana and M.S. degree in Immunology from Southern Illinois University at Edwardsville.

Image of Jonas Niaura

Previously Mr. Niaura served as Head of Search and Evaluation for Infection, Neuroscience and GI at AstraZeneca. Prior to that, he served as Sr. Director Business Development for AMAG Pharmaceuticals from 2008 until 2011. From 2002 to 2008 Mr. Niaura served as Director of Business Development for Achillion Pharmaceuticals.

Mr. Niaura attended the University of Illinois at Urbana-Champaign where he earned a BS in Chemistry and Chemical Engineering and the Yale School of Management where he received his MBA.

Image of Edward Lee PhD

Edward Lee joined Biota on August 4th 2014.

Dr. Edward R Lee was Vice President and Head of Chemical Development at Blend Therapeutics from April 2012 until November 2013, where novel platinum compounds and nanotechnology were combined to create innovative oncology therapies. Prior to that, he was Vice President and Head of Chemical Process Development at Genzyme Corporation. In a career spanning 22 years at Genzyme he was responsible for the development of small molecules and polymers to treat numerous diseases, including cystic fibrosis, multiple sclerosis and Gaucher Disease. Edward held a post-doctoral position at the University of Bern, Switzerland, from 1988 to1990, investigating vitamin B12 chemistry.

Dr. Lee received a BSc in Chemistry from the University of Warwick, UK and a PhD in Chemistry from the University of Warwick, UK

Image of Uday Patel

Uday Patel joined Biota as Vice President of Regulatory Affairs in June 2014.

Mr. Patel has been a partner and key member of senior management and scientific project teams in successful start-ups to clinical stage organizations. Mr. Patel’s background includes international experience in program management, clinical operations, regulatory affairs, analytical development and quality assurance. Most recently, he served as Vice President of Regulatory Affairs and Quality Assurance at Inhibitex, Inc. from 2010 to 2012. He was responsible for development and implementation of regulatory strategy for various clinical programs and management of QA tasks in clinical development of infectious disease therapies. Prior to joining Inhibitex, he was Vice President of Regulatory/Quality at Peptimmune from 2004 to 2010, responsible for execution of regulatory and quality initiatives focused on autoimmune indications and metabolic diseases.

Mr. Patel received a B.S. degree in Biochemistry from Suffolk University and Master of Liberal Arts (ALM) degree in Biology from Harvard University. Mr. Patel has received regulatory affairs certification (RAC) for US and EU from the regulatory affairs professionals society (RAPS).

Log In

Create an account